2822 recruiting. 2822 Phase 1, 1209 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 2822 | Recruiting 2822 |
| Phase 2 | 1209 | Recruiting 1209 |
Follow Neoplasms: new trials by email Literature Review of Neoplasms trials Research Report on Neoplasms
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| AMC 120, Glofitamab Plus Chemoimmunotherapy in Newly Diagnosed HIV-Associated Large B-Cell Lymphoma (The "Glofit-RCHOP Study") Biopsy Procedure, Biospecimen Collection, Bone Marrow Aspiration - AIDS-Related Diffuse Large B-cell Lymphoma, Diffuse Large B-Cell Lymphoma, Not Otherwise Specified | Phase 1 | Recruiting | National Cancer Institute (NCI) | 15 | 2027-07-05 | 2026-11-05 |
| Testing the Addition of Iberdomide to Therapy in People With Neuroblastoma That Has Come Back, Not Responded to Treatment, or Gotten Worse Bone Marrow Aspiration, Bone Marrow Biopsy, Computed Tomography - Recurrent Ganglioneuroblastoma, Recurrent Neuroblastoma | Phase 1 / Phase 2 | Recruiting | National Cancer Institute (NCI) | 76 | 2027-06-25 | 2026-11-06 |
| Testing the Combination of Anti-Cancer Drugs, Selumetinib and DS-8201a (Trastuzumab Deruxtecan), for Advanced Pancreatic Ductal Adenocarcinoma Biospecimen Collection, Diagnostic Imaging Testing, Echocardiography Test - Advanced Pancreatic Ductal Adenocarcinoma, Metastatic Pancreatic Ductal Adenocarcinoma | Phase 1 / Phase 2 | Recruiting | National Cancer Institute (NCI) | 31 | 2027-06-01 | 2026-10-22 |
| Testing the Investigational Medication Combination of Teclistamab and Pomalidomide Compared to the Usual Treatment (Carfilzomib, Pomalidomide, and Dexamethasone) for Patients With Multiple Myeloma Who Have Relapsed Shortly After Treatment Biospecimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy - Recurrent Multiple Myeloma, Refractory Multiple Myeloma | Phase 1 / Phase 2 | Recruiting | National Cancer Institute (NCI) | 162 | 2027-04-12 | 2026-10-16 |
| Testing the Effect of Teclistamab on Recurrent Plasmablastic Lymphoma Biospecimen Collection, Computed Tomography, Positron Emission Tomography - Recurrent Plasmablastic Lymphoma, Refractory Plasmablastic Lymphoma | Phase 1 | Recruiting | National Cancer Institute (NCI) | 30 | 2027-03-26 | 2026-10-20 |
| Testing the Addition of an Anti-Cancer Drug, Camonsertib, to Radiation Therapy for Recurrent Head and Neck Squamous Cell Carcinoma Biospecimen Collection, Camonsertib, Computed Tomography - Clinical Stage III HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8, Recurrent Head and Neck Squamous Cell Carcinoma | Phase 1 | Recruiting | National Cancer Institute (NCI) | 39 | 2027-02-13 | 2026-10-29 |
| Safety and Efficacy of Early Second Infusion of Axi-cel Based on ctDNA for R/R Large B - Cell Lymphoma Infusion of Axicabtagene Ciloleucel - Relapsed/Refractory Diffuse Large B-cell Lymphoma | Phase 1 / Phase 2 | Recruiting | Zhujiang Hospital | 15 | 2027-02-01 | 2025-03-30 |
| DK222 Study at Hopkins [18F]DK222 radiotracer - Non-Small Cell Lung Cancer, Urothelial Cancer | Phase 1 | Recruiting | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | 6 | 2027-01-31 | 2026-09-29 |
| Testing the Safety of Anti-Cancer Drug, CX-5461 (Pidnarulex), in Treating Lymphoma With Specific Changes in the MYC Gene Biopsy Procedure, Biospecimen Collection, Computed Tomography - Burkitt Lymphoma, Double-Expressor Lymphoma | Phase 1 / Phase 2 | Recruiting | National Cancer Institute (NCI) | 50 | 2027-01-11 | 2026-10-14 |
| Belinostat in Combination With Azacitidine or Pralatrexate for the Treatment of Relapse or Refractory T-cell Lymphoma Azacitidine, Belinostat, Biospecimen Collection - Recurrent Anaplastic Large Cell Lymphoma, Recurrent Enteropathy-Associated T-Cell Lymphoma | Phase 1 | Recruiting | City of Hope Medical Center | 40 | 2027-01-03 | 2026-10-30 |
| Lurbinectedin With Osimertinib in Transformed Small Cell Lung Cancer Lurbinectedin, Osimertinib - Small Cell Lung Cancer ( SCLC ), Transformed Small Cell Lung Cancer | Phase 1 / Phase 2 | Recruiting | Misty Shields | 16 | 2027-01-01 | 2026-10-15 |
| HER2 Vaccine for Locally Advanced Breast Cancer HER2 Vaccine - Breast Cancer, HER2-positive Breast Cancer | Phase 1 | Recruiting | Pravin T.P Kaumaya | 36 | 2027-01-01 | 2026-11-05 |
| Golcadomide in Combination With Rituximab for the Treatment of Patients With Relapsed or Refractory Mantle Cell Lymphoma Biopsy Procedure, Biospecimen Collection, Bone Marrow Biopsy - Recurrent Mantle Cell Lymphoma, Refractory Mantle Cell Lymphoma | Phase 1 / Phase 2 | Recruiting | City of Hope Medical Center | 58 | 2026-12-21 | 2026-10-22 |
| Lactulose to Improve Gut Health in Cancer Patients Receiving Immunotherapy Lactulose - Cancer | Phase 1 / Phase 2 | Recruiting | University of Chicago | 55 | 2026-12-15 | 2026-06-16 |
| ANO31905 in Combination With Chemotherapy for CLDN18.2-Positive Locally Advanced Unresectable or Metastatic Pancreatic Cancer ANO31905, AG [gemcitabine+nab-paclitaxel], mFOLFIRINOX [Oxaliplatin+irinotecan+leucovorin+fluorouracil] - Pancreatic Cancer | Phase 1 / Phase 2 | Recruiting | Anova Innovation Limited | 84 | 2026-12-01 | 2026-10-23 |
| Panitumumab-IRDye800 to Detect Pediatric Neoplasms During Neurosurgical Procedures Panitumumab-IRDye800, Pinpoint-IR9000 endoscopic/handheld device, Explorer Air camera - Brain Tumor | Phase 1 / Phase 2 | Recruiting | Stanford University | 12 | 2026-12-01 | 2026-09-29 |
| TCR1188-ABC Cells in KRAS-mutated Cancers TCR1188-ABC cells, Fludarabine + Cyclophosphamide combination, Tocilizumab - Cholangiocarcinoma, Colorectal Cancer | Phase 1 | Recruiting | University of Pennsylvania | 30 | 2026-12-01 | 2026-10-14 |
| Lymphodepletion With Low Dose Total Body Irradiation Before Standard of Care Tisagenlecleucel for the Treatment of Relapsed and Recurrent Large B-cell Lymphoma Biospecimen Collection, Computed Tomography, Cyclophosphamide - Recurrent Diffuse Large B-Cell Lymphoma, Refractory Diffuse Large B-Cell Lymphoma | Phase 1 | Recruiting | Nathan Denlinger | 18 | 2026-12-01 | 2026-10-09 |
| A Study of LP-118 In Combination With Ponatinib, Dexamethasone And Blinatumomab For Adults With Newly-Diagnosed, BCR::ABL1-Positive Acute Lymphoblastic Leukemia (ALL) LP-118 - Philadelphia Positive Acute Lymphoblastic Leukemia | Phase 1 | Recruiting | Wake Forest University Health Sciences | 26 | 2026-12-01 | 2026-10-29 |
| FH-WT1-E50 TCR T Cells With Azacitidine for the Treatment of Minimal Residual Disease Positive Acute Myeloid Leukemia Autologous HLA-A*02:01-restricted CD4+/CD8+ Anti-WT1 TCR/CD8ab-expressing T-cells, Azacitidine, Biospecimen Collection - Acute Myeloid Leukemia | Phase 1 | Recruiting | Fred Hutchinson Cancer Center | 9 | 2026-12-01 | 2026-10-29 |
Showing 20 of 2822. Sign in to see all of them.
Carcinoma, Non-Small-Cell Lung (336) · Colorectal Neoplasms (235) · Neoplasm Metastasis (229) · Breast Neoplasms (224) · Leukemia, Myeloid, Acute (222) · Recurrence (172) · Ovarian Neoplasms (171) · Pancreatic Neoplasms (158) · Prostatic Neoplasms (148) · Multiple Myeloma (147) · Melanoma (135) · Squamous Cell Carcinoma of Head and Neck (129) · Lung Neoplasms (127) · Stomach Neoplasms (126)
Neoplasms by Histologic Type (1649) · Neoplasms by Site (1646) · Hemic and Lymphatic Diseases (844) · Neoplasms, Glandular and Epithelial (674) · Immune System Diseases (619) · Digestive System Diseases (605) · Immunoproliferative Disorders (596) · Lymphoproliferative Disorders (594) · Digestive System Neoplasms (580) · Hematologic Diseases (574) · Pathological Conditions, Signs and Symptoms (532) · Urogenital Diseases (512) · Pathologic Processes (510) · Urogenital Neoplasms (492)
Cyclophosphamide (186) · pembrolizumab (158) · fludarabine (145) · Specimen Handling (139) · Magnetic Resonance Spectroscopy (125) · Biopsy (106) · Carboplatin (75) · Nivolumab (69) · Bevacizumab (68) · venetoclax (67) · Cisplatin (55) · Gemcitabine (52) · Paclitaxel (50) · Azacitidine (49) · Dexamethasone (49)
M.D. Anderson Cancer Center (94) · National Cancer Institute (NCI) (92) · Memorial Sloan Kettering Cancer Center (50) · City of Hope Medical Center (41) · AstraZeneca (31) · Beijing Biotech (29) · Sichuan Baili Pharmaceutical Co., Ltd. (29) · Merck Sharp & Dohme LLC (25) · Washington University School of Medicine (23) · Mayo Clinic (22) · West China Hospital (22) · Chinese PLA General Hospital (18) · Baylor College of Medicine (17) · Second Affiliated Hospital, Zhejiang University, School of Medicine (17) · Janssen Research & Development, LLC (16)
United States (1694) · China (855) · Spain (285) · Australia (272) · France (225) · South Korea (197) · United Kingdom (195) · Canada (157) · Italy (150) · Japan (145) · Germany (134) · Taiwan (109) · Netherlands (101) · Belgium (84) · Israel (72)
Jason Wu (7) · Weidong Han, Ph.D (6) · Christopher G Kanakry, M.D. (4)
PMID 41671463, PMID 40056080, PMID 42013378, PMID 31401903, PMID 35175355, PMID 36375120, PMID 38640255, PMID 40513054, PMID 41100731, PMID 41118600, PMID 41276366, PMID 41621809, PMID 41980020, PMID 42850140, PMID 10845900, PMID 11937001, PMID 12049861, PMID 12663454, PMID 12675312, PMID 13680158, PMID 14998846, PMID 15173079, PMID 15331400, PMID 15844174, PMID 15897941, PMID 15975518, PMID 16200343, PMID 16344433, PMID 16530701, PMID 16609072, PMID 16786120, PMID 16899365, PMID 16983123, PMID 17664336, PMID 17705175, PMID 18172267, PMID 18509186, PMID 18997826, PMID 19058754, PMID 19097774, PMID 19212170, PMID 19221744, PMID 19223865, PMID 19282026, PMID 19534336, PMID 19760366, PMID 20167817, PMID 20627894, PMID 20660832, PMID 20728210
2025 (94), 2023 (89), P30CA033572 (40), UM1CA186709 (9), UM1CA186689 (8), P30CA138292 (6), 2017 (5), 2018 (5), 2019 (5), UM1CA186688 (5), P30CA093373 (4), UM1CA186690 (4), UM1CA186717 (4), UM1CA228823 (4), P30CA014089 (3)